Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

ClinicalTrials.gov ID: NCT01058434

Public ClinicalTrials.gov record NCT01058434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multi-center, Non-randomized, Open-label Study of TKI258 in Patients With Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4;14) Translocation

Study identification

NCT ID: NCT01058434
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 43 participants

Conditions and interventions

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

TKI258 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 30, 2010
Primary completion: Jan 31, 2013
Completion: Jan 31, 2013
Last update posted: Dec 18, 2020

2010 – 2013

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst.	Mobile	Alabama	36688	—
Central Hematology Oncology Medical Group	Alhambra	California	91801	—
Central Coast Medical Oncology Corporation	Santa Maria	California	93454	—
St. Jude Heritage Medical Group Virginia Crosson Cancer Center	Yorba Linda	California	92886	—
Kootenai Medical Center Kootenai Medical Center	Coeur d'Alene	Idaho	83814	—
Hematology and Oncology Specialists Dept of Hem&Onc Specialist - 2	Metairie	Louisiana	70006	—
Mayo Clinic - Rochester Rochester	Rochester	Minnesota	55905	—
Memorial Sloan Kettering Cancer Center MSKCC	New York	New York	10021	—
Duke University Medical Center Dept. of DUMC (4)	Durham	North Carolina	27710	—
Lancaster Cancer Center	Lancaster	Pennsylvania	17601	—
Cancer Centers of the Carolinas Dept. of CC of the Carolinas	Greenville	South Carolina	29605	—
University of Tennessee Cancer Institute SC-2	Memphis	Tennessee	38104	—
University of Texas Southwestern Medical Center UTSW Medical Center	Dallas	Texas	75390-8527	—
University of Wisconsin SC	Madison	Wisconsin	53792	—
Medical College of Wisconsin Med College of Wisconsin	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01058434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2020 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01058434 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →